



#### **REMARKS**

Applicants in their prior Amendment of claim 4 inadvertently deleted the definition of R<sup>15</sup>. This Amendment reinserts this definition and is not new matter.

Favorable consideration and allowance of claims 1-19 and 25-31 is respectfully requested.

If any additional fees are incurred as a result of the filing of this paper, authorization is given to charge deposit account number 23-0785.

Respectfully submitted,

R<sub>V</sub>·

Martin L. Katz (Reg. No. 25,011)

Attorney for Applicant

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER 500 MADISON STREET, SUITE 3800 CHICAGO, IL 60661 (312) 876-1800

# **CERTIFICATE OF MAILING**

I hereby certify that this Supplemental Amendment is being deposited with the U.S. Postal Service via First Class Mail to: Commissioner for Patents, Washington, DC 20231 on December 31, 2002.


Kim Annel

### MARKED UP VERSION OF CLAIMS

JAN 0 7 2003

Please amend claim 4 as follows:

### 4. (twice amended) A compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N,  $CR^1$ ,  $C(R^2)(R^3)$ ,  $NR^5$  and CH;

q is an integer of from 3 to 6;

T is (CH<sub>2</sub>)<sub>b</sub> wherein b is an integer of 0 to 2;

L is (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer of 0 or 1;

W is selected from the group consisting of C and CR<sup>15</sup>;

B is H or alkyl;

R<sup>1</sup> at each occurrence is independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, - CF<sub>3</sub>, -NH<sub>2</sub>, -OH, NHC(O)N(C<sub>1</sub>-C<sub>3</sub> alkyl), - NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>3</sub> alkyl), alkylamino, di(C<sub>1</sub>-C<sub>3</sub> alkyl)amino,cycloalkyl, aryl, arylamino, heterocyclyl and sulfonamido;

R<sup>1</sup> and R<sup>3</sup> are hydrogen;

R<sup>4</sup> is selected from the group consisting of hydrogen, alkyl, aryl, biaryl, heterocyclyl, alkylaryl, aralkyl, heterocyclylalkyl and alkylheterocyclyl;

R<sup>5</sup> at each occurrence is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclylalkyl, heterocyclyl and aryloxyalkyl;

R<sup>6</sup> and R<sup>7</sup> are independently hydrogen or alkyl;

R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen, alkyl and halogen; and

## R<sup>15</sup> is hydrogen;

wherein B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>15</sup> are unsubstituted or substituted with at least one electron donating or electron withdrawing group; and wherein when at least one Y is CR<sup>1</sup>, R<sup>1</sup> and R<sup>6</sup> taken together

or a pharmaceutically acceptable salt thereof.

may form a ring;